Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
7.05
+0.49 (7.47%)
Nov 10, 2025, 4:00 PM EST - Market closed
Evolus Revenue
Evolus had revenue of $68.97M in the quarter ending September 30, 2025, with 12.90% growth. This brings the company's revenue in the last twelve months to $285.82M, up 15.10% year-over-year. In the year 2024, Evolus had annual revenue of $266.27M with 31.76% growth.
Revenue (ttm)
$285.82M
Revenue Growth
+15.10%
P/S Ratio
1.58
Revenue / Employee
$860,913
Employees
332
Market Cap
456.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 266.27M | 64.19M | 31.76% |
| Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
| Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
| Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
| Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EOLS News
- 2 days ago - Evolus, Inc. (EOLS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Evolus Reports Third Quarter 2025 Financial Results - Business Wire
- 13 days ago - Evolus to Participate in 2025 Stifel Healthcare Conference - Business Wire
- 19 days ago - Evolus to Report Third Quarter Financial Results on November 5, 2025 - Business Wire
- 4 weeks ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch - PRNewsWire
- 2 months ago - Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer - Business Wire